Please wait while we retrieve your external webpage
Decoupling treatment from diagnosis is a critical priority in prostate cancer. Low and very low risk patients are appropriate candidates for active surveillance. It is encouraging to see molecular tests emerge that may help identify patients who are at low risk from their disease.
You must be logged in to post a comment.
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.